News
NETRF-funded Research Sets the Stage for Study Exploring Use of Terbium-161 in NETs
A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.
Study Focuses on Matching Patients with Rare Cancers and Cancer of Unknown Primary to Targeted Treatments
A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).
“It was my students’ idea…”
Warwick, NY middle school Ukulele club raises $6,000 for NETRF
A Champion for NETRF
“Anything that I have done, and any impact I have made in support of NETRF is because of the lessons he taught me.” Erica Roberts, NETRF Champion Society Member
“In my heart, I don’t ever want anyone to experience what we endured.”
After Leanne lost her husband of 31 years to pancreatic neuroendocrine cancer (pNETs), she sold his most beloved possession, a Bass boat, and donated half of the proceeds to NETRF. Leanne, her son Justin and their family and friends have raised more than $35,000 in Michael’s name for NETRF. She shares their story.
New Clinical Trial Testing Chemotherapy After Surgery in High-Risk pNETs
A new phase II clinical trial is exploring the effects of two approved chemotherapy drugs administered after surgery to treat adult patients who have high-risk, well-differentiated pancreatic neuroendocrine tumors (pNETS).
Faces of Philanthropy:
Joe Castrovinci
Joe Castrovinci has been living with NETs (and living well!) since his diagnosis in 2012. Read about his NET journey and why he and his husband have included NETRF in their estate planning.
Brandon’s Extraordinary Legacy
He was just FUN. Simply the nicest guy – always thinking of others. Perpetually positive – he only saw the glass as ‘half full.’ He
First World NET Forum featured NETRF-funded Researchers
The European Neuroendocrine Tumor Society (ENETS) held its 19th Annual Conference earlier this month in Barcelona, Spain. The meeting brings together physicians and researchers from throughout the world to discuss the latest research on neuroendocrine cancer. More than 1500 participants attended in person or virtually. This year the meeting included the first World NET Forum, focusing on basic and translational science. NETRF was proud to sponsor the prizes for best abstracts.
NETRF Achieves Highest 4-Star Rating from Charity Navigator
The Neuroendocrine Tumor Research Foundation is thrilled to announce that it has achieved a 4-star rating from Charity Navigator for the seventh consecutive year for